Paclitaxel drug-coated balloon angioplasty for de novo coronary lesions in an expanded real world clinical setting: the multicenter ALLIANCE registry
Cardiovascular Intervention and Therapeutics · 2026-07 · 41 (3) · 628-638
DOI: 10.1007/s12928-026-01280-4 ↗Kurz gefasst
Äquivalenzstudie in der Zeitschrift Cardiovascular Intervention and Therapeutics, online erschienen am 08.04.2026. Verfasst von Masato Nakamura und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Minimally Invasive Treatment in Cardiovascular Medicine, Toho University Ohashi Medical Center, 2-22-36, Ohashi, Meguro-Ku, Tokyo, 153-85…. Hauptthemen laut MEDLINE: Angioplasty, Balloon, Coronary, Coated Materials, Biocompatible, Coronary Artery Disease, Paclitaxel. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Despite limited clinical evidence, the use of drug-coated balloons (DCB) in percutaneous coronary intervention for de novo coronary lesions is expanding and increasing. ALLIANCE is a prospective, multicenter, all-comer registry designed to evaluate the efficacy and safety of the paclitaxel-DCB in an expanded real-world clinical setting. A calculated sample size of 1500 patients was expected to provide 95% power to detect non-inferiority against a performance goal of 7.5% target lesion failure (TLF) at 1 year with a 3.0% absolute non-inferiority margin. Cases in which DCB was performed after successful lesion preparation were consecutively enrolled. The Primary endpoint was TLF, a composite of cardiac death, myocardial infarction and clinically driven target lesion revascularization (cd-TLR) at 1 year. An independent clinical events committee adjudicated all primary endpoint events. Between July 2023 and February 2024, 1794 patients (with 1984 lesions) were enrolled at 57 sites in Japan. Mean age was 71 years, 76% of patients were male, 45% had diabetes mellitus, and 29% presented with acute coronary syndromes. Among lesion characteristics, 31% were calcified lesions, and 34% were treated a greater than 3 mm DCB balloon. Intravascular imaging was used in 88.5% of lesions. Lesion preparation was performed with modified balloons in 68% of cases and by atherectomy in 19%. Bail-out stenting after DCB was required in 1.1% of patients. The rate of TLF at 1 year was 4.7% overall (95%CI 3.8–5.8%, pnon-inferiority < 0.001), and cd-TLR 2.9%. Paclitaxel DCB demonstrated favorable safety and efficacy profiles in the current expanding clinical practice. Japan Registry of Clinical Trials (jRCT1032230218). https://jrct.mhlw.go.jp .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Minimally Invasive Treatment in Cardiovascular Medicine, Toho University Ohashi Medical Center, 2-22-36, Ohashi, Meguro-Ku, Tokyo, 153-8515, Japan. masato@oha.toho-u.ac.jp.
- Division of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan.
- Department of Cardiovascular Medicine, Kurashiki Central Hospital, Kurashiki, Japan.
- Department of Cardiology, Fujita Health University Hospital, Toyoake, Japan.
- Department of Cardiology, Sapporo Cardio Vascular Clinic, Sapporo, Japan.
- Department of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan.
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Nakamura, M., Tanabe, K., Kadota, K., Muramatsu, T., Tadano, Y., Ando, K., Nakamura, S., Ashikaga, T., Kinoshita, Y., Kuriyama, N., Onishi, Y., Kataoka, T., Nishida, K., Iijima, R., Nozoe, M., Morishige, K., Takahashi, T., Murakami, Y., Kozuma, K., & ALLAINCE registry investigators (2026). Paclitaxel drug-coated balloon angioplasty for de novo coronary lesions in an expanded real world clinical setting: the multicenter ALLIANCE registry. Cardiovascular Intervention and Therapeutics, 41(3), 628-638. https://doi.org/10.1007/s12928-026-01280-4
Vancouver
Nakamura M, Tanabe K, Kadota K, Muramatsu T, Tadano Y, Ando K, et al. Paclitaxel drug-coated balloon angioplasty for de novo coronary lesions in an expanded real world clinical setting: the multicenter ALLIANCE registry. Cardiovascular Intervention and Therapeutics. 2026;41(3):628-638. doi:10.1007/s12928-026-01280-4
BibTeX
@article{Nakamura2026,
author = {Nakamura, Masato and Tanabe, Kengo and Kadota, Kazushige and Muramatsu, Takashi and Tadano, Yutaka and Ando, Kenji and Nakamura, Shigeru and Ashikaga, Takashi and Kinoshita, Yoshihisa and Kuriyama, Nehiro and Onishi, Yuko and Kataoka, Toru and Nishida, Koji and Iijima, Raisuke and Nozoe, Masatsugu and Morishige, Kunio and Takahashi, Takefumi and Murakami, Yoshitaka and Kozuma, Ken and ALLAINCE registry investigators, ALLAINCE registry investigators},
title = {Paclitaxel drug-coated balloon angioplasty for de novo coronary lesions in an expanded real world clinical setting: the multicenter ALLIANCE registry},
journal = {Cardiovascular Intervention and Therapeutics},
year = {2026},
volume = {41},
number = {3},
pages = {628--638},
doi = {10.1007/s12928-026-01280-4}
}
EUVIMED